OpSens Inc. - President & CEO, Louis Laflamme, holding the OptoWire.
President & CEO, Louis Laflamme, holding the OptoWire.
Source: Les Affaires.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • OpSens Inc. (OPS), has been awarded a national group purchasing agreement for interventional specialty diagnostics with Premier Inc.
  • Premier members have had access to special pricing and terms for the OptoWire III system and related components for about 254,000 facilities
  • OptoWire is a pressure guidewire to help diagnose, treat, and confirm results in coronary arteries
  • Over 150,000 patients have been evaluated or treated with OptoWire
  • OpSens Inc.(OPS) is up 3.11 per cent and is trading at $2.32 per share as of 12:26 p.m. ET

Medical device company, OpSens (OPS), has been awarded a national group purchasing agreement for interventional specialty diagnostics with Premier Inc.

As of July 1st, the new agreement has allowed members of the healthcare improvement company, Premier, to take advantage of special pricing and terms pre-negotiated by Premier for OptoWire III and related system components. Premier has roughly 254,000 facilities under its wing.

OpSens stated its OptoWire is a modern pressure guidewire designed for contemporary clinical practice to help in the diagnosis, treatment, and confirmation of results in coronary arteries.

OptoWire has been designed to offer physicians competitive advantages such as superior steerability, reliability in coronary physiologic assessments, and a single guidewire for the required procedure. The company claims it helps save staff costs and time.

The wire allegedly navigates through complex anatomies, delivers a small tube without guidewire exchange, gives choices for different active and resting indicators to assess coronary physiology, and confirmation of treatment with easy and reliable post-intervention measurements.

Since its approval, over 150,000 patients have been evaluated or treated with OptoWire.

“Collaborations like this one are an integral part of our strategy to expand the commercialization of the OptoWire in the U.S. and internationally, by increasing our cath lab access… OpSens now has contracts in place covering over 90 per cent of hospitals in the U.S. through group purchasing agreements,” Louis Laflamme, President and CEO of OpSens, said.

OpSens Inc.(OPS) is up 3.11 per cent and is trading at $2.32 per share as of 12:26 p.m. ET.

More From The Market Herald

" MCI Onehealth (TSX:DRDR) and Euclid Telehealth work to improve patient vision

MCI Onehealth (DRDR) and Euclid Telehealth are collaborating to increase access to care that can potentially prevent vision loss among Ontario patients.

" Spectral Medical (TSX:EDT) reports Q2 2022 results

Spectral Medical (EDT) released its financial results for the second quarter ended June 30, 2022.

" Hemostemix (TSXV:HEM) closes second tranche of non-brokered private placement

Hemostemix (HEM) has closed the second tranche of a non-brokered private placement of units for gross proceeds of $1,364,710.10.

" Nova Leap Health (TSXV:NLH) posts 2nd highest Q2 results in its history

Nova Leap Health (NLH) released its financial results for the quarter ended June 30, 2022.